Literature DB >> 22914624

Engineering approaches to immunotherapy.

Melody A Swartz1, Sachiko Hirosue, Jeffrey A Hubbell.   

Abstract

As the science of immunology grows increasingly mechanistic, motivation for developing quantitative, design-based engineering approaches has also evolved, both for therapeutic interventions and for elucidating immunological pathways in human disease. This has seeded the nascent field of "immunoengineering," which seeks to apply engineering analyses and design approaches to problems in translational immunology. For example, cell engineers are creating ways to tailor and use immune cells as living therapeutics; protein engineers are devising new methods of rapid antibody discovery; biomaterials scientists are guiding vaccine delivery and immune-cell activation with novel constructs; and systems immunologists are deciphering the evolution and maintenance of T and B cell receptor repertoires, which could help guide vaccine design. The field is multidisciplinary and collaborative, with engineers and immunologists working together to better understand and treat disease. We discuss the scientific progress in this young, yet rapidly evolving research area, which has yielded numerous start-up companies that are betting on impact in clinical and commercial translation in the near future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914624     DOI: 10.1126/scitranslmed.3003763

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  76 in total

Review 1.  Pediatric Vaccine Adjuvants: Components of the Modern Vaccinologist's Toolbox.

Authors:  David J Dowling; Ofer Levy
Journal:  Pediatr Infect Dis J       Date:  2015-12       Impact factor: 2.129

2.  Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates.

Authors:  Gregor Fuhrmann; Andrea Grotzky; Ružica Lukić; Simon Matoori; Paola Luciani; Hao Yu; Baozhong Zhang; Peter Walde; A Dieter Schlüter; Marc A Gauthier; Jean-Christophe Leroux
Journal:  Nat Chem       Date:  2013-06-09       Impact factor: 24.427

3.  Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.

Authors:  Alexandre de Titta; Marie Ballester; Ziad Julier; Chiara Nembrini; Laura Jeanbart; André J van der Vlies; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

4.  Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells.

Authors:  Frances C Knight; Pavlo Gilchuk; Amrendra Kumar; Kyle W Becker; Sema Sevimli; Max E Jacobson; Naveenchandra Suryadevara; Lihong Wang-Bishop; Kelli L Boyd; James E Crowe; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2019-10-04       Impact factor: 15.881

5.  Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.

Authors:  Anton Beletskii; Ashley Galloway; Shyam Rele; Michele Stone; Frank Malinoski
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

7.  Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64.

Authors:  Parijat Bhatnagar; Zheng Li; Yoonsu Choi; Jianfeng Guo; Feng Li; Daniel Y Lee; Matthew Figliola; Helen Huls; Dean A Lee; Tomasz Zal; King C Li; Laurence J N Cooper
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 8.  Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity.

Authors:  Peng Tan; Lian He; Gang Han; Yubin Zhou
Journal:  Trends Biotechnol       Date:  2016-09-28       Impact factor: 19.536

Review 9.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

10.  Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.

Authors:  Krystina L Hess; James I Andorko; Lisa H Tostanoski; Christopher M Jewell
Journal:  Biomaterials       Date:  2016-11-30       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.